Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in TNF inhibitor-experienced radiographic axial spondyloarthritis
NL-OMON43396Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ASAS40 response. Started Jul 2016; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON43396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43396.